Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad383 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Julia Herrou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, INSERM UMR 1153, Université de Paris-Cité, APHP Centre, Cochin Hospital, 75014 Paris, France. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets, Enthesopathy, Hypophosphatemia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Context
Musculoskeletal complications are the main manifestations in adults with X-linked hypophosphatemia (XLH). Enthesopathy significantly impairs quality of life.
Objective
To identify the risk factors associated with the development and progression of spinal enthesopathies in adults with XLH. Design and setting We conducted a retrospective study in the French Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism. Patients Adults XLH patients with 2 EOS® imaging performed at least 2 years apart at the same center between June 2011 and March 2022. The progression of enthesopathies was defined as a new enthesopathy at least 1 intervertebral level in patients with or without presence of enthesopathy at baseline. Main outcome measures Demographic, treatment, PHEX mutation with the progression of enthesopathies.
Results
Fifty-one patients (66.7% of women, mean age 42.1 ± 13.4 years) underwent 2 EOS imaging with an average interval of 5.7 (± 2.31) years. Progression of spinal enthesopathies was observed in 27 (52.9%) patients. In univariate analysis, patients with a progression of spinal enthesopathies were significantly older (P < .0005), were significantly older at treatment initiation (P = .02), presented with dental complications (P = .03), received less frequently treatment during childhood with phosphate and/or vitamin D analogs (P = .06), and presented more frequently with hip osteoarthritis (P = .002) at baseline. In multivariate analysis, none of these factors was associated with a progression of spinal enthesopathies.
Conclusion
This study confirms the high proportion of patients with a progression of spinal enthesopathies. Age seems to be the main factor associated with progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, INSERM UMR 1153, Université de Paris-Cité, APHP Centre, Cochin Hospital, 75014 Paris, France.
- Department of Rheumatology, APHP Centre, Cochin Hospital, 75014 Paris, France.
- Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network for Rare Bone and Calcium Phosphate Disorders, Paris, France.
- Department of Endocrinology and Diabetes for Children, APHP, Bicêtre Paris Saclay Hospital, 94270 Le Kremlin Bicêtre, France.
- APHP, Plateforme d'expertise Paris Saclay maladies rares, Bicêtre Paris Saclay Hospital, 94270 Le Kremlin Bicêtre, France.
- Université Paris-Saclay, INSERM UMR-S 1185, Physiologie et Physiopathologie Endocriniennes, 94270 Le Kremlin-Bicêtre, France.
ORCID-Profile: Julia Herrou, Agnès Linglart, Karine Briot
Zitieren
APA
Herrou, J., Fechtenbaum, J., Rothenbuhler, A., Kamenický, P., Roux, C., Linglart, A., & Briot, K. (2023). Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad383
Vancouver
Herrou J, Fechtenbaum J, Rothenbuhler A, Kamenický P, Roux C, Linglart A, et al. Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad383
BibTeX
@article{Herrou2023,
author = {Herrou, Julia and Fechtenbaum, Jacques and Rothenbuhler, Anya and Kamenický, Peter and Roux, Christian and Linglart, Agnès and Briot, Karine},
title = {Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad383}
}
EUVIMED